<sup>68</sup>Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients

Qi, Changsong; Guo, Rui; Chen, Yan; Li, Chenzhen; Liu, Chang; Zhang, Miao; Zhang, Cheng; Zhang, Xiaotian; Hou, Xingguo; Chen, Bo; Jia, Bing; Yang, Zhi; Shen, Lin; Zhu, Hua

doi:10.2967/jnumed.123.267110

Cited by 6 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To assess the binding affinity of 123 I-IMAB362 Biosimilar, enzyme-linked immunosorbent assays were performed following protocols outlined in a prior study . In brief, CLDN18.2 protein plates were prepared as previously described, and varying concentrations of 123 I-IMAB362 Biosimilar (0.001, 0.01, 0.1, 1.0, 10, 20, 50, 100, and 300 nM, 100 μL per well, n = 3) were added.…”

Section: Materials and Methodsmentioning

confidence: 99%

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Wu,

Chen,

Zhao

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

clinical benefit in patients with advanced gastroesophageal cancers. The noninvasive assessment of CLDN18.2 expression through molecular imaging offers a potential avenue for expedited monitoring and the stratification of patients into risk groups. This study elucidates that CLDN18.2 is expressed at a noteworthy frequency in primary gastric cancers and their metastases. The iodogen method was employed to label IMAB362 with 123 I/ 131 I. The results demonstrated the efficient and reproducible synthesis of 123 I-IMAB362, with a specific binding affinity to CLDN18.2. Immuno-single-photon emission computed tomography (SPECT) imaging revealed the rapid accumulation of 123 I-IMAB362 in gastric cancer xenografts at 12 h, remaining stable for 3 days in patient-derived tumor xenograft models. Additionally, tracer uptake of 123 I-IMAB362 in MKN45 cells surpassed that in MKN28 cells at each time point, with tumor uptake correlating significantly with CLDN18.2 expression levels. Positron emission tomography/computed tomography imaging indicated that tumor uptake of 18 F-FDG and the functional/viable tumor volume in the 131 I-IMAB362 group were significantly lower than those in the 123 I-IMAB362 group on day 7. In conclusion, 123 I-IMAB362 immuno-SPECT imaging offers an effective method for direct, noninvasive, and whole-body quantitative assessment of tumor CLDN18.2 expression in vivo. This approach holds promise for accelerating the monitoring and stratification of patients with gastric cancer.

show abstract

Section: Materials and Methodsmentioning

confidence: 99%

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Wu,

Chen,

Zhao

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer

Wang,

Bai,

Zhong

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Trends in cancer imaging

Zhou,

Shi,

Huang

et al. 2024

Trends in Cancer

View full text Add to dashboard Cite

⁶⁸Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients

Abstract: Visual Abstract

Cited by 6 publications

References 18 publications

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer

Trends in cancer imaging

Contact Info

Product

Resources

About

68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients

Abstract: Visual Abstract

Cited by 6 publications

References 18 publications

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer

Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer

Trends in cancer imaging

Contact Info

Product

Resources

About

⁶⁸Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients